Introduction
Cytochrome P450 (P450*) is a large family of hemoproteins and responsible for the biotransformation of a broad group of *Abbreviations: ADH, alcohol dehydrogenase; CYP, cytochrome P450 (for individual form); EROD, ethoxyresorufin O-deethylase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IQ, 2-amino-3-methylimidazo [4,5-f] quinoline; 3-MC, 3-methylcholanthrene; MeIQx, 2-amino-3,8-dimethylimidazo [4,5-f] quinoxaline; MMLV, moloney murine leukemia virus; P450, cytochrome P450; P450 reductase, NADPH-cytochrome P450 reductase; PhIP, 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine; PCB, polychlorinated biphenyls (Kaneclor KC-500); PCR, polymerase chain reaction; RT, reverse transcriptase; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; Tris, 2-amino-2-hydroxymethyl-1,3-propanediol.
The nucleotide sequence data reported in this paper appear in the DDBJ, EMBL and GenBank database with accession number 'D86475', definition 'Callithrix jacchus adult liver mRNA for cytochrome P-450'.
© Oxford University Press 1985 structurally unrelated compounds including drugs, environmental pollutants, procarcinogens and endogenous substrates. P450 is divided into gene families and subfamilies according to the degree of identities in their amino acid sequences (1) . It has also been recognized that qualitative and quantitative species differences in P450s are present among animals, including humans (2) , which is one of the reasons for difficulty in extrapolating to humans the data obtained with experimental animals.
Since monkeys are considered to be genetically close to humans than rodents, Old World monkey such as cynomolgus monkeys (Macaca fascicularis) and rhesus monkeys (Macaca mulatta) are used to predict the in vivo cytotoxicity and carcinogenicity of drugs and other compounds (3, 4) . However, the extensive use of these large Old World monkeys is inconvenient and limited for several reasons: They are difficult to handle because of their large body size, ferocity and poor fertility. On the other hand, New World monkeys, especially marmosets (Callithrix jacchus), have several advantages over many other primates: They are much easier to handle because of their smallness and good fertility. In recent years, a number of reports in which the New World monkey is used as an experimental animal has appeared (5, 6) . Nevertheless, little information is available on the molecular properties of marmoset P450 except for our previous report (7) .
In vitro studies of human and rodent CYP1A2s have shown that this P450 catalyses the N-hydroxylation of procarcinogenic heterocyclic amines, suggesting that CYP1A2 plays important roles in the carcinogenesis of such chemicals (8) (9) (10) (11) . Therefore, clarification of the expression level and the catalytic properties of CYP1A2 in livers is one of the necessary steps to know if the marmoset is a suitable experimental model for predicting toxicity of heterocyclic amines in vivo.
With respect to the expression of CYP1A2 in monkey livers, it has been reported that the level of the cytochrome in the liver of cynomolgus monkeys is very low (12) (13) (14) (15) . On the other hand, according to the results of immunoblot analyses and the results of assay for the activity of purified P450 or liver microsomes with typical substrates of CYP1A2, it has been suggested that the CYP1A2 is expressed constitutively in marmoset livers (13, 16, 17) . However, it remains to provide firm evidence for the existence of CYP1A2. Thus, in the present study, we obtained cDNA clone encoding marmoset CYP1A2 and determined the expression level by S1 nuclease protection assay and reverse transcriptase-polymerase chain reaction (RT-PCR) as one step to realise the ultimate objective. The catalytic activity of marmoset CYP1A2 was also compared to that of human and cynomolgus monkey CYP1A2.
Materials and methods

Materials
Restriction enzymes, S1 nuclease and other DNA-modifying enzymes were obtained from Takara Shuzo (Kyoto, Japan), Moloney murine leukaemia virus (MMLV) reverse-transcriptase from United States Biochemical (Cleveland, OH), native Pfu DNA polymerase from Stratagene (La Jolla, CA), Sequenase Ver. 2 DNA sequencing kit form Amersham (Aylesbury, UK), dye primer cycle sequencing kit from Perkin Elmer (Norwalk, CT), 2-amino-3-methylimidazo [4,5- 
Animals
Ten adult female common marmosets (Callithrix jacchus), as well as an adult female and three adult male cynomolgus monkeys (Macaca fascicularis) were used in this study. Three female marmosets were given a single i.p. injection of PCB in corn oil at a dose of 300 mg/kg. Three male cynomolgus monkeys and two female marmosets were given a single i.p. injection of 3-MC in corn oil at a dose of 20 mg/kg. Each monkey was killed 3 days later. Liver and other organs were immediately excised and used for the preparation of RNA and microsomes.
Screening of cDNA library and sequence determination
Total RNA fraction was prepared from a liver of an untreated marmoset according to the method of Chirgwin et al. (18) . A cDNA library was prepared as described previously (19) . Screening of cDNA library was carried out with plaque hybridization using radio-labelled DNA probes. Phage DNA of positive plaques was subcloned into pBluescript KS(Ϫ) vector by in vitro excision. The nucleotide sequence was determined by the dideoxy method (20) with Sequenase Ver. 2 sequencing kit and dye primer cycle sequencing kit. The nucleotide sequence was analysed with Genetyx (Ver. 8.0, SDC Software, Tokyo, Japan).
Amplification and sequence determination of marmoset CYP1A2 cDNA
The primers used in this study were synthesized with a DNA synthesizer (Model 381A; Applied Biosystems, Foster City, CA). The sequence of the primers used for RT-PCR are as follows:
MART-1F, 5Ј-TTACAACCCTGCCAATCTCAAG-3Ј; MART-1R, 5Ј-AAGTCCTGATAGTGTTCCTGG-3Ј; MART-2F, 5Ј-AAGAACCCGCACCTGGCACT-3Ј; MART-2R, 5Ј-TCCCACTTGCCCAGAACCTC-3Ј; MART-3F, 5Ј-ATCTTTGGAGCAGGTTTGAT-3Ј; MART-3R, 5Ј-TTTTTGAGACGGAGTTTCGCT-3Ј.
RT-PCR was performed as described previously (T.Sakuma, M.Hieda, S.Ohgiya, R.Nagata and T.Kamataki, submitted). The RT-PCR products were purified by electrophoresis in a 1% agarose gel. The nucleotide sequences were directly determined by the di-deoxy method with a dye primer cycle sequencing kit and an automated DNA sequencer (Model 377; Applied Biosystems, Foster City, CA). The primers used for sequence determination were the same oligonucleotides used for the amplification.
S1 nuclease protection assay
For the S1 nuclease protection assay, a 157 nucleotide-long single strand DNA encompassing position 1239 to 1383 of marmoset CYP1A2 was prepared. The 12 nucleotide-long segment in this probe, which was located at the 3Ј downstream of CYP1A2 cDNA, was an unhybridizable segment which came from the M13 vector. This segment could be cut off by S1 nuclease. Other details were the same as described previously (19) .
Analysis of the level of CYP1A2 mRNA by RT-PCR
Total RNA fraction was prepared from liver samples of marmosets, cynomolgus monkeys and humans according to the method of Chirgwin et al. (18) . RT-PCR was performed as described previously (T.Sakuma, M.Hieda, S.Ohgiya, R.Nagata and T.Kamataki, submitted). Oligonucleotide primers were selected according to the genomic structure of human CYP1A2 reported by Quattrochi et al. (21) using Genetyx software. The forward and reverse primers were 5Ј-ATCTCCTGGAGCCTCATGTA-3Ј and 5Ј-GTTGTGCCCTTGTTGTGCT-3Ј, respectively. Both primers completely matched to CYP1A2 of the marmoset, the cynomolgus monkey and the human. The PCR was performed at cycles appropriate for respective samples, with 94°C for 60 s, 58°C for 90s and then 72°C for 120 s. Numbers of the PCR cycle were as follows: untreated marmosets, an untreated cynomolgus monkey and humans, 31 cycles; 3-MCtreated marmosets, polychlorinated biphenyls (PCB)-treated marmosets and 3-methylcholanthrene (3-MC)-treated cynomolgus monkeys, 27 cycles. Within these cycles, the amount of PCR products from respective liver samples increased exponentially (Figure 1 ). The efficiency of amplification seemed to be equal among RNA samples from marmosets, cynomolgus monkeys and humans. The product length was 209 bp, scanning the region from 1006 to 1214 of marmoset CYP1A2 cDNA. In human CYP1A2 gene, the corresponding region contains the 4th and the 5th intron sequences of 266 and 800 bp, respectively. When the mixture of RT reaction was incubated without RT as negative control experiments, no RT-PCR product was amplified (data not shown). Based on these observations, we have considered that amounts of RT-PCR products reflect the initial amount of respective CYP1A2 mRNA. The forward primer also shows perfect agreement to CYP1A1 of cynomolgus monkeys and humans. The reverse one has only one or two nucleotide differences to CYP1A1 of humans and cynomolgus monkeys, respectively. Thus, it was not able to exclude the possibility for amplification of CYP1A1 cDNA using this primer set. Therefore, to verify the amplification of the CYP1A2 cDNA and to measure the level of it, the PCR products were digested with Pvu II, a restriction enzyme that can digest CYP1A2, but CYP1A1, then resolved by 12% polyacrylamide gel electrophoresis. During PCR cycles, amplifitory efficiencies of the Pvu II digests (CYP1A2 cDNA) and the undigested PCR products (CYP1A1 or other related cDNA) were not changed (data not shown). To normalize the applied RNA quantity and quality, portions of the cDNA samples were simultaneously amplified by PCR using primers for human GAPDH (Clontech, Palo Alto, CA). The forward and reverse primers were 5Ј-ACCACAGTCCATGCCATCAC-3Ј and 5Ј-TCCAC-CACCCTGTTGCTGTA-3Ј, respectively. The PCR condition for GAPDH was the same as that of CYP1A2. Exponential amplification of GAPDH cDNA was also confirmed (data not shown). The PCR products length was 452 bp with spliced an intron of 104 bp. The nucleotide sequences and the expression level of marmoset and cynomolgus monkey GAPDH are not available so far. However, cDNAs with the expected size were amplified using this primer set from both monkey samples. The levels of those RT-PCR products seemed to be equal. On the other hand, in the case of human samples, amounts of PCR products were lower than those from monkey samples. However, when the amount of 28S rRNA of each total RNA sample stained with ethidium bromide in an agarose gel and the amounts of GAPDH cDNA amplified were compared, good correlation was observed among all RNA samples examined (r ϭ 0.905). We considered that low levels of PCR products from human samples were due to partial degradation of human RNA samples caused from the time before storage. Based on these observations, we considered that we could normalize the applied RNA quantity and quality with the amount of amplified GAPDH cDNA. Therefore, expression level of CYP1A2 mRNA in the liver of respective primates was shown as a ratio of CYP1A2 to GAPDH.
Expression of marmoset CYP1A2 in recombinant yeast
The MART-4P, a RT-PCR product containing the entire coding region of marmoset CYP1A2, was amplified using MART-4F and MART-4R primers and used to construct a yeast expression plasmid. The nucleotide sequences of each primer area as follows:
MART-4F, 5Ј-GATGGCATTGTCCCAGTTTGTT-3Ј; MART-4R, 5Ј-GAAGAGAACGAGGGCTGAGTC-3Ј;
This RT-PCR product was blunted at both ends by T4 DNA polymerase and then kinated by T4 polynucleotide kinase followed by downstream insertion into the alcohol dehydrogenase (ADH) promoter in the pAAH5 yeast expression vector. The resulting plasmid (pCM1A2) and the other two expression plasmids for human CYP1A2 (pHM1A2) and cynomolgus monkey CYP1A2 (pMK1A2) were used to transform the High-red yeast (M8 line) by the lithium acetate method (22) . The pHM1A2 and pMK1A2 were constructed through the same strategy to pCM1A2 as described previously (T.Sakuma, M.Hieda, S.Ohgiya, R.Nagata and T.Kamataki, submitted). The nucleotide sequences of the three expression constructs were confirmed before use. Those of pCM1A2 and pHM1A2 were completely identical to that determined by the other three RT-PCR products and that reported by Jaiswal et al. (23) , respectively. The nucleotide sequence of pMK1A2 was completely identical to that determined by the same methodology applied to marmoset CYP1A2 (T.Sakuma, M.Hieda, S.Ohgiya, R.Nagata and T.Kamataki, submitted). The High-red yeast is a recombinant strain of Saccharomyces cerevisiae YPH500, which shows high P450 reductase activity (M8 line; 635 nmol cyt.c reduction/ min/mg protein) by the integration of the expression unit of hamster P450 reductase into yeast genome (24) . Cultivation of recombinant yeasts and preparation of microsomal fractions were carried out as described previously (19) . The concentrations of P450 and protein were determined as reported by Omura and Sato (25) , and Lowry et al. (26) , respectively.
Analyses of enzyme activities
P450-mediated activation of heterocyclic amines was measured by determination of the expression of the umu gene in Salmonella typhimurium TA1535/ pSK1002 according to the method of Shimada and Okuda (27) . EROD activity was measured by the method of Sinjari et al. (28) with minor modifications. Briefly, the reaction mixture containing 0.1 M Tris-HCl (pH 7.8), 250 µM NADPH, 1 mg of yeast microsomes and 5 µM ethoxyresorufin in a final volume of 0.5 ml was incubated at 37°C for 20 min. The reaction was terminated by addition of 2 ml of ice-cold methanol. After centrifugation at 1000 g for 15 min, the amounts of resorufin in aqueous solution were measured by their fluorescence intensity (ex., 574 nm; em, 596 nm).
Results
Isolation and amplification of marmoset CYP1A2 cDNA
A cDNA library prepared from the liver RNA of an untreated marmoset was screened using human CYP1A2 cDNA as a probe. From~1ϫ10 5 plaques, 54 positive clones were obtained. Among these clones, only one clone (CM1A2-9) containing 704 bp insert DNA showed high identity in nucleotide sequence to human CYP1A2. No positive clones were obtained in the rescreening of this library using an oligonucleotide probe specific to CM1A2-9 cDNA clone. We previously reported that marmoset CYP2D19 and CYP3A21 showed~90% identities in nucleotide sequences to corresponding forms in humans and in cynomolgus monkeys (7) . Additionally, we could amplify cynomolgus monkey CYP1A2 cDNA using sets of primer specific to human CYP1A2 under appropriate conditions (T.Sakuma, M.Hieda, S.Ohgiya, R.Nagata and T.Kamataki, submitted). Thus, we tried to amplify the cDNA of marmoset CYP1A2 by RT-PCR, and the cDNA was subjected to determination of the nucleotide sequences. Complementary DNA was synthesized from the liver total RNA of a PCB-treated marmoset with MMLV reverse-transcriptase. Three cDNA fragments, namely MART-1P, MART-2P and MART-3P, were amplified with native Pfu DNA polymerase. The MART-1P, encompassing the amino-terminal half of the coding region and the 5Ј-non-coding region of marmoset CYP1A2, was obtained using primers specific to human CYP1A2. The MART-2P, encompassing the middle portion of the coding region, was obtained using a sense primer specific to human CYP1A2 and an antisense primer specific to the CM1A2-9 cDNA clone. In the case of MART-3P, encompassing the carboxy-terminal half of the coding region and the 3Ј-noncoding region, sense and antisense primers specific to the sequences of MART-2P and CM1A2-9 cDNA clone, respectively, were used. The nucleotide sequences of overlapping regions among RT-PCR products were completely identical. However, when the nucleotide sequence of MART-3P was compared with that of the CM1A2-9 cDNA clone, one nucleotide difference resulting in one amino acid substitution appeared at the 1495th. To search for other differences, all nucleotide sequences of CYP1A2 in the untreated marmoset, which is the source of the CM1A2-9 cDNA clone, were directly determined from RT-PCR products. However, other nucleotide differences could not be found. The nucleotide in question was further examined in three marmosets. Conclusively, four marmosets had adenine at the 1495th nucleotide and encoded isoleucine of the 489th residue. On the other hand, only one marmoset had guanine and encoded valine. The nucleotide and the deduced amino acid sequences of marmoset CYP1A2 are shown in Figure 2 . The length of the mRNA derived from the four RT-PCR products and a cDNA clone was 1944 nucleotides long. This contained an open reading frame (position from 31 to 1578) encoding a polypeptide of 516 residues. The haem-binding cysteine was observed at the 458th residue. Table I shows the comparison of CYP1A genes among primates. The amino acid sequence of marmoset CYP1A2 showed 90.5 and 88.2% identities to CYP1A2 of the cynomolgus monkey and human, respectively, and showed lower identities (Ͻ70.0%) to CYP1A1 genes. The high identities to CYP1A2 clearly indicate that the cDNAs obtained in this study coded for marmoset CYP1A2.
Expression of CYP1A2 in the liver and other organs
It is known that CYP1A2 is expressed specifically in the liver, and the expression was increased by treatment with PCB and polycyclic aromatic hydrocarbons. Thus, to clarify if CYP1A2 was specifically expressed in the liver, and to examine its inducibility by PCB, an S1 nuclease protection assay was carried out. As shown in Figure 3 , a considerable level of signal was detected in the liver of untreated marmosets, and the level was increased by PCB-treatment. On the other hand, no signal was detected in the kidney, small intestine and lung of untreated marmoset, and in the kidney and small intestine of PCB-treated marmoset. It is therefore confirmed that amongst the tissues examined, the predominant expression of CYP1A2 mRNA was in the liver.
The expression level of CYP1A2 mRNA in the liver of marmosets, cynomolgus monkeys and humans was compared by RT-PCR method. We have considered that we could measure relative level of CYP1A2 mRNA in the liver of the three primates using RT-PCR on the basis of that described in the Materials and methods section. The result of this analysis was shown in Figure 4 . Expression of CYP1A2 mRNA in the liver of untreated primates was observed in marmosets and humans, and the level of marmosets was approximately one-quarter of humans. On the other hand, expression was not detected in the liver of one untreated cynomolgus monkey used in this study. Treatment with 3-MC or PCB elevated marmoset CYP1A2 mRNA to a 4-or 6-fold higher level, respectively. Treatment with 3-MC also induced CYP1A2 mRNA in the liver of cynomolgus monkeys. However, it was one third and one tenth of untreated and 3-MC-treated marmosets, Fig. 3 . S1 nuclease protection assay for the expression of CYP1A2 mRNA in the liver and extrahepatic tissues of marmosets. Twenty micrograms of total RNA were digested by S1 nuclease, and the digest was applied to acrylamide gel electrophoresis. UN, organs from untreated marmosets; PCB, organs from a polychlorinated biphenyls-treated marmoset.
respectively. These results indicate that the expression level of CYP1A2 mRNA in the liver of untreated marmosets is higher than 3-MC-treated cynomolgus monkeys and it was lower than that of humans. 
Expression of recombinant marmoset CYP1A2 protein in yeast
To confirm that amplified cDNA encoded P450, and to examine whether marmoset CYP1A2 showed catalytic activities, marmoset CYP1A2 (valine-type) was expressed in the high-red yeast. Human CYP1A2 and cynomolgus monkey CYP1A2 were also expressed to compare the catalytic activities with marmoset CYP1A2. An absorption peak at 447 nm was observed in the reduced carbon monoxide-difference spectrum from microsomes of the yeast cells transformed with pCM1A2 (data not shown). On the other hand, no absorption peak around 450 nm was observed in the spectrum from microsomes of control yeast cells which was transformed with pAAH5. This result indicates that cDNA amplified in this study encoded P450.
Enzymatic activities of marmoset CYP1A2
The capacity of marmoset CYP1A2 to activate IQ MeIQx and PhIP was examined in the umu mutagenicity test. The results are shown in Figure 5 . Marmoset CYP1A2 efficiently activated IQ and MeIQx. PhIP was also activated by this enzyme, but to a lesser extent. The capacities of marmoset CYP1A2 to activate IQ and PhIP were lower than those seen with human and cynomolgus monkey CYP1A2. MeIQx was activated most efficiently by cynomolgus monkey CYP1A2, followed by the CYP1A2 of the marmoset and human. The activity of marmoset CYP1A2 to metabolize ethoxyresorufin, a known typical substrate for CYP1A, was examined. As shown in Table II , marmoset CYP1A2 was capable of catalysing the O-deethylation of ethoxyresorufin. The activity of marmoset CYP1A2 was higher than that of human CYP1A2, and lower than that of cynomolgus monkey CYP1A2. 
Discussion
It has been demonstrated that CYP1A2 plays important roles in the mutagenic activation of heterocyclic amines (8) (9) (10) (11) . Recently, Shimada and colleagues reported that humans express quite a high level of CYP1A2;~13% of total P450 in livers could be accounted for by the CYP1A2 (29) . On the other hand, it has been shown that the expression of CYP1A2 in the liver of the untreated cynomolgus monkey was very low (12) (13) (14) (15) . These findings raised the question of whether or not the cynomolgus monkey is a suitable experimental animal to predict the cytotoxicity and carcinogenicity of drugs and environmental pollutants. In recent years, the presence of constitutive CYP1A2 in the liver of untreated marmosets has been reported (13, 16, 17) . Thus, in order to confirm the constitutive expression, we first isolated cDNA fragments of marmoset CYP1A2 through the combination of cDNA cloning and RT-PCR, and proved the expression by S1 nuclease protection assay. The nucleotide sequence of marmoset CYP1A2 determined in this study was 1944 bp, and contained the entire coding region and the 5Ј-and 3Ј-non-coding regions. The characteristic feature of marmoset CYP1A2 cDNA is the presence of an Alu-like sequence in the 3Ј-non-coding region as seen in human CYP1A2 (22) . It was located from 1685 to the 3Ј-end.
The constitutive and liver-specific expression of CYP1A2 in marmosets was confirmed by the S1 nuclease protection assay and RT-PCR. Induction of CYP1A2 expression by typical CYP1A inducers such as 3-MC and PCB was also demonstrated. This expression profile was in parallel with that of human CYP1A2 (30, 31) , suggesting that both marmoset and human CYP1A2 were under the same or similar control mechanism.
As shown in Figure 2 , one nucleotide difference yielding one amino acid replacement was observed at the 489th residue. We used a native Pfu DNA polymerase in PCR amplification, and the sequence determination of RT-PCR products was carried out directly without subcloning into a vector. Thus, it is likely that this difference was due to an allelic variant of the CYP1A2 gene, not due to a mistake in PCR. The influence of this difference has not been examined yet. No evidence has been reported so far on the importance of the residue in the activity of CYP1A2 to our knowledge. Uno and colleagues (32) , however, reported the importance of C-terminal 28-residues on the activity and the stereospecificity of P450 forms belonging to the CYP2C subfamily. Therefore, it is necessary to examine the influence of this difference by a heterogeneous expression system.
Recently, Kastner and Neubert purified seven forms of P450 from liver microsomes of untreated and TCDD-treated marmosets (17, 33) . In the forms purified, one form named as 'form D' showed EROD activity and an immunoreactivity to an anti-peptide antibody against rat CYP1A2. Based on these observations, they concluded that form D was CYP1A2. In accordance with this report, marmoset CYP1A2 expressed in the high-red yeast also showed EROD activity. In the umu mutagenicity test, marmoset CYP1A2 expressed in yeast showed a capability to activate IQ, MeIQx and PhIP. While the activity of CYP1A2 of marmosets and humans differed to some extent, both CYP1A2 showed considerable activities toward procarcinogenic heterocyclic amines. Taking this together with the constitutive expression of CYP1A2 in marmoset livers, it seems that marmoset CYP1A2 has a capability to contribute to the activation of procarcinogens as supposed in humans. However, it is well known that outcome of exposure of organism to chemical carcinogens would be varied from various factors such as activities of the activating and detoxicating enzymes, and from level of endogenous compounds such as glutathiones. For instance, mutagenicity of heterocyclic amines is dependent on the activity of N-acetyltransferase besides that of CYP1A2 (11) . Therefore, further studies are necessary to establish the usefulness of the marmoset in toxicological and pharmacological studies.
